Synopsis

In this presentation I will describe how at SSPC we are developing predictive modelling methods to guide experiment in developing special requirements of new, more complex active ingredients. Through the example of Trastuzumab (Herceptin®), an antibody used to treat breast cancer, I will show how rationally designed drug carrier materials can potentially improve therapeutic activity both by shielding fragile biopharmaceuticals from proteolytic degradation and targeting specific receptors in vivo. Antibody therapy generally requires parenteral injection to attain the required bioavailability and pharmacokinetics, but improved formulations of this kind may slow enzymatic degradation of the antibody in the gastrointestinal tract, permitting the use of noninvasive oral delivery.